Toragen reports positive safety data update from Cohort 2 of its phase 1 clinical trial of TGN-S11

Toragen Inc, a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from Cohort 2 of its phase 1 trial of TGN-S11, its first drug candidate, in patients with HPV-associated cancers.

Toragen is primarily focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (HPV). No safety issues identified in Cohort 2. Now the company is proceeding to Cohort 3, for which patients have been identified and it also proceeding to expansion phase for which patients are being recruited.

This phase 1 trial is an open-label, non-randomized study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The study is being conducted in two parts: a dose escalation part and dose expansion part. The dose escalation consists of five Cohorts of three to six patients. The dose expansion will now begin in parallel with Cohort 3 of the dose escalation. Level 1 of the dose expansion part of the phase 1 trial will be in combination with a PD-1 checkpoint inhibitor.

“Having this early safety signal for our dose escalation portion of our Phase 1 trial is yet another early milestone for Toragen,” said Dr. Sandra Coufal, Toragen’s CEO. “By beginning the dose expansion portion of the Phase 1 trial in an accelerated timeframe, we bring hope of meeting an unmet medical need for HPV-cancer patients by possibly enhancing the efficacy of the PD-1 checkpoint inhibitor.”

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!